Hepatitis C as a metabolic disease by Patrice Andre
INVITED SPEAKER PRESENTATION Open Access
Hepatitis C as a metabolic disease
Patrice Andre
From 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)
Marseille, France. 23-25 May 2012
Before liver cirrhosis and hepatocellula carcinoma can
develop, the early and long lasting features of hepatitis C
are host metabolism modifications with a specific and so
far unique metabolic syndrome that may associate insulin
resistance, liver steatosis and hypo-betalipoproteinemia.
These metabolic perturbations are directly induced by
heptatitis C virus (HCV) replication and regress after viral
suppression. Symmetrically HCV depends on glucose and
lipid metabolism for its replication.
HCV induced insulin resistance is both hepatic and
peripheral. The insulin receptor pathway is impacted at
several steps by viral proteins with probable functional
consequences. Mechanism of peripheral insulin resistance
remains obscure and the viral signals send to adipose tis-
sue or muscles have to be identified. One major IR meta-
bolic consequence might contribute to the mobilization of
free fatty acids from periphery to the liver and to the con-
stitution of liver steatosis. Importantly, HCV modifies with
genotype-specific differences, the synthesis, degradation
and secretion of lipid in a coordinated fashion to promote
the accumulation of neutral lipids.
The lipid droplets (LD) that are the lipid storage orga-
nelles are mandatory platforms for the assembly of infec-
tious viral particles. In particular localization of core
protein and NS5A on LD and mobilization of the LD are
essential steps that control viral infectivity. Interestingly,
the efficiency of HCV to the LD disposal and use corre-
lates to viral production and may influences the extent of
hepatic accumulation of lipids.
The most striking association of HCV with lipid meta-
bolism resides in the coincidence of the betalipoproteins
and viral particles pathways with the formation of unique
hybrid viral particles. Indeed HCV depends on a func-
tional very low density lipoproteins (VLDL) assembly and
secretion process to be secreted. HCV also modifies at
different degree the VLDL composition forming sub viral
particles, which are minimally modified VLDL that bear
the viral envelop glycoproteins, or hybrid viral particles
known as lipo-viral-particles (LVP), which contain all the
viral and VLDL components that are highly infectious.
Functions of these hybrid particles on the disease features
and progression as well as therapeutic targets remain to
be fully characterized.
Thus, HCV appears to have developed an original and
so far unique way with major clinical consequences to
modify and use the lipid metabolism to persist in the host.
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